Medtronic Partners With Qualcomm To Expand Type 2 Diabetes Focus
This article was originally published in The Gray Sheet
Executive Summary
A new partnership between Medtronic and Qualcomm will focus on new wireless continuous glucose monitor designs targeting type 2 diabetics. The deal further broadens Qualcomm's reach into the medical device industry.
You may also be interested in...
Medtronic Builds Toward Integrated Care With A String Of Diabetes Deals
Medtronic inking four diabetes deals in about a month's time is no coincidence. The company wants to transform itself from a device maker that sells mostly to type 1 diabetics, into an integrated-care company that serves the broader diabetes community, and it does not have all the capabilities it needs to accomplish that feat in house, explains Hooman Hakami, who heads Medtronic's diabetes unit.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.